ERBB2 and breast cancer: A recent retrospective paper by Tianien et al. suggested that a high MLR could have a detrimental role in terms of overall survival and BC-specific survival in early BC patients; however, high NLR and MLR correlated with poor survival among HER2+ patients only in the subgroup that did not receive adjuvant trastuzumab [7].